Regeneron Pharmaceuticals reported positive Phase III results for garetosmab in fibrodysplasia ossificans progressiva (FOP), a rare disease causing abnormal bone formation. The drug significantly reduced new bone lesions compared to placebo and is slated for FDA approval filings by year's end. Garetosmab, an antibody neutralizing activin A implicated in disease progression, represents a breakthrough therapeutic in a patient population with significant unmet medical needs. The success highlights Regeneron's robust pipeline and commitment to rare disease innovation.